Patients seeking the common abortion pill mifepristone will still be able to access the medication. The federal Fifth Circuit Court of Appeals has ruled to stay a decision by a lower-court judge in Texas, who had overturned the Food and Drug Administration’s approval of the drug more than 20 years ago.
What happens next is uncertain, but the Biden administration has asked the Supreme Court to take up the issue. We discuss the latest developments in the case and what may happen next with Catherine Weiss, a partner at the Lowenstein Sandler law firm and chair of the Lowenstein Center for the Public Interest, part of a national network of lawyers advising clients on the case.
